CXCR4 and hepatocellular carcinoma: Recent studies have shown that increasing CXCL12 expression in HCC models alleviated hypoxia and increased the recruitment of immunosuppressive cells, whereas using a PD-1 inhibitor in combination with CXCR4 inhibition and sorafenib inhibited HCC growth [68].